Compare BROS & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BROS | BIO |
|---|---|---|
| Founded | 1992 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7700 |
| Industry | Restaurants | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.2B |
| IPO Year | 2021 | N/A |
| Metric | BROS | BIO |
|---|---|---|
| Price | $64.02 | $304.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | $77.16 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 2.7M | 155.9K |
| Earning Date | 02-11-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.73 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | $1,537,335,000.00 | ★ $2,557,500,000.00 |
| Revenue This Year | $28.88 | $1.62 |
| Revenue Next Year | $25.56 | $2.26 |
| P/E Ratio | $126.52 | ★ N/A |
| Revenue Growth | ★ 28.93 | N/A |
| 52 Week Low | $47.16 | $211.43 |
| 52 Week High | $86.88 | $373.69 |
| Indicator | BROS | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 44.66 |
| Support Level | $62.25 | $298.78 |
| Resistance Level | $64.25 | $307.07 |
| Average True Range (ATR) | 1.73 | 7.77 |
| MACD | 0.17 | -0.88 |
| Stochastic Oscillator | 77.05 | 35.90 |
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.